The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV Non-small cell lung cancer

被引：0
作者：
Li, Liuning [1 ]
Liu, Jiaying [2 ]
Chai, Xiaoshu [1 ]
Zhang, Liwen [1 ]
Chen, Zhijian [1 ]
He, Chunxia [1 ]
Hong, Hongxi [1 ]
机构：
[1] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China
[2] Guangzhou Univ Chinese Med, Guangzhou, Guangdong, Peoples R China
来源：
2014 IEEE INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICINE (BIBM) | 2014年
关键词：
Non-small cell Lung cancer; Cytokine-induced killer cells; Adjuvant immunotherapy; Xiaoji decoction; Effectiveness;
D O I：
暂无
中图分类号：
TP39 [计算机的应用];
学科分类号：
081203 ; 0835 ;
摘要：
Objective: To evaluate the clinical efficacy and safety of cytokine-induced killer (CIK) cells immunotherapy in combination with platinum chemotherapy and Xiaoji decoction in patients with advanced stage non-small cell lung cancer (NSCLC). Methods: Patients with advanced stage NSCLC were randomly assigned to Group A (platinum chemotherapy plus xiaoji decoction) and Group B (platinum chemotherapy plus xiaoji decoction and CIK cell transfusion). Progression free survival (PFS), disease control rate (DCR), overall response rate (ORR) , Karnofsky score (KPS), host cellular immune response and treatment related side effects were assessed. Results: Patients in Group B had significantly longer PFS than those in Group A. The overall response rate (ORR) and the disease control rate (DCR) showed no statistical difference between the Group B and Group A The level of CD3(+), CD4(+) were significantly higher after treatment, The level of CD3(+) in Group A was significant lower after treatment. There were no immediate adverse reactions between the 2 groups. Conclusion: This study suggest that CIK cells immunotherapy combined with platinum chemotherapy and Xiaoji decoction may become an effective strategy to improve the survival and prolong the PFS of patients with advanced stage NSCLC.
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of cetuximab combined with chemotherapy in Chinese patients with advanced non-small cell lung cancer
    Si, Xiaoyan
    Zhang, Li
    [J]. THORACIC CANCER, 2012, 3 (02) : 188 - 193
  • [42] A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines
    Li, Yutao
    Sharma, Amit
    Wu, Xiaolong
    Weiher, Hans
    Skowasch, Dirk
    Essler, Markus
    Schmidt-Wolf, Ingo G. H.
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage IIIB-IV Non-small Cell Lung Cancer
    Akerley, Wallace
    Boucher, Kenneth M.
    Bentz, Joel S.
    Arbogast, Kylee
    Walters, Theodore
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (02) : 214 - 219
  • [44] A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Ukena, D
    Berg, M
    Leutz, M
    Zell, L
    Schlimmer, P
    Sybrecht, GW
    [J]. LUNG CANCER, 1998, 19 (01) : 31 - 36
  • [45] Adjuvant cytokine-induced killer cell immunotherapy improves long-term survival in patients with stage I-II non-small cell lung cancer after curative surgery
    Huang, Jianmin
    Zhao, Xuan
    Zhang, Zhen
    Yang, Shuangning
    Chen, Xinfeng
    Shen, Chunyi
    Wang, Liping
    Qi, Yu
    Zhang, Yi
    [J]. CYTOTHERAPY, 2023, 25 (02) : 202 - 209
  • [46] Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer
    Wang, Zibing
    Liu, Xiaoli
    Till, Brian
    Sun, Miaomiao
    Li, Xiang
    Gao, Quanli
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [47] Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer
    Fathi, Amir T.
    Brahmer, Julie R.
    [J]. SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 210 - 216
  • [48] Chemotherapy for early stage non-small cell lung cancer
    Kris, MG
    Azzoli, CG
    [J]. LUNG CANCER, 2001, 34 : S49 - S52
  • [49] Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia After First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells
    Hui, Zhenzhen
    Zhang, Xinwei
    Ren, Baozhu
    Li, Runmei
    Ren, Xiubao
    [J]. FRONTIERS IN IMMUNOLOGY, 2015, 6 : 1 - 5
  • [50] Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer
    Sovak, Mika A.
    Lutzker, Stuart
    Zheng, Ling
    Guensch, Lisa
    Joyce, Margaret
    Schwartz, Susan
    Wu, Yujun
    Aisner, Joseph
    [J]. LUNG CANCER, 2006, 53 (02) : 177 - 181
12345